Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.41 |
| ▸ | CA3 | P07451 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065879 | 0.87 | CYP19A1 (0.44) | CYP19A1CA12CA1CA2CA9 | |
| SCHEMBL782596 | 0.84 | CA2 (0.44) | CYP19A1CA12CA1CA2CA9 | |
| SCHEMBL19201046 | 0.80 | CYP19A1 (0.50) | CYP19A1CA12CA1CA2CA9 | |
| SCHEMBL4456811 | 0.78 | CA1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27935675 | 0.75 | CA1 (0.47) | CYP19A1CA12CA1CA2CA9 | |
| SCHEMBL30865768 | 0.74 | CA1 (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1759251 | 0.74 | CA1 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7887355 | 0.73 | GAA (0.42) | CA12CA1CA2CA9CA3 | |
| SCHEMBL20257485 | 0.73 | CA1 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27970653 | 0.73 | MAPT (0.50) | CYP19A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797870-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING 1-[1-PHENYL-CYCLOBUTYL]ISOBUTYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | Revivia Pharmaceuticals, Inc. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9695116-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| CN-104039753-B | The compositions of phenylcycloalkyl methylamine derivative, synthesis and using method | 雷维瓦药品公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-04-28 | — | — | US | disclosed |
| US-9238625-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2797870-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | Reviva Pharmaceuticals, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2013102195-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | CYP19A1 85/4885CA12 3181/4885CA1 3296/4885 |
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | PNMT, HTR6, COMT | CYP19A1 85/4885CA12 3181/4885CA1 3296/4885 |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | CYP19A1 85/4885CA12 3181/4885CA1 3296/4885 |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | CYP19A1 85/4885CA12 3181/4885CA1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.